Cook Medical Australia has announced a new partnership with local biotechnology company Anteo Technologies to conduct a feasibility study, applying their patented Mix&Go technology.
The feasibility study is the first between Cook Medical Australia's Asia-Pacific Technologies (ANT) team and an Australian company.
Anteo Technologies owns the patented Mix&Go technology, which enables the attachment of biomolecules to synthetic surfaces.
According to Dr Geoff Cumming, CEO of Anteo Technologies, "Anteo will be formally assessing an opportunity to apply Anteo's patented Mix&Go technology to once of Cook's portfolio applications. This is a fully funded program, and our first commercial foray into the in vivo medical devices sector."
Director of Operations and R&D at Cook Medical APAC, Dr Samih Nabulsi said the study was an exciting development for the ANT Team.
"The AMT Team is made up of scientists, engineers and business directors tasked with identifying medical device innovations from across the entire region with potential for commercialisation that can further enhance patient care worldwide. This is the first announcement of an approved concept identified through this initiative.
"Since the formation of the ANT Team at the beginning of 2014 there have been 141 concepts that have come to the group, exceeding our expectations. This is one of four approved projects in the pipeline which will then go through the feasibility phase of research and development. If successful this paves the way to exciting technological advancement," said Dr Nabulsi.
Anteo Technologies and Cook Medical Australia both support advanced manufacturing in Australia.
The study follows a smaller paid scoping study that Anteo undertook with Cook Australia last year as part of their work exploring opportunities in new, non-core areas.